{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"552.287","value":"1165.52"},{"groupId":"OG001","spread":"388.844","value":"1114.23"},{"groupId":"OG002","spread":"388.557","value":"1311.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"774.257","value":"1426.70"},{"groupId":"OG001","spread":"616.737","value":"1289.33"},{"groupId":"OG002","spread":"497.856","value":"1551.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Cycle 1 Day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, once daily (QD) for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 20 cycles. Participants with locally advanced or metastatic solid tumors with no standard therapeutic alternative in the United States were included in this cohort.","id":"OG000","title":"Western Safety Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.","id":"OG001","title":"Pancreatic Cancer Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.","id":"OG002","title":"Metastatic CRC Cohort"}],"paramType":"MEAN","populationDescription":"PK Analysis Set included all participants for whom there was sufficient dosing and TAK-931 concentration-time data to reliably estimate the PK parameters. As prespecified in the protocol, data for intensive PK sampling was collected only for participants in Western Safety Cohort, Pancreatic Cancer Cohort, and Metastatic CRC Cohort. Number analyzed is the number of participants with data available for analysis at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (each cycle = 21 days) Days 1 and 8 pre-dose and at multiple timepoints (up to 24 hours) post-dose","title":"AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-931","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}